ArticleDiscover oncology2025
Radiotherapy versus no radiotherapy for rectal neuroendocrine carcinoma patients treated with surgery and chemotherapy: a population-based cohort study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChemotherapy is regularly recommended for surgically rectal neuroendocrine carcinoma (NEC) patients. However, the additional benefit of perioperative radiotherapy for these patients is unclear to date. This study aims to evaluate the outcome of radiotherapy in rectal NECs who treated with surgery and chemotherapy.
methodsThis is a retrospective controlled study based on SEER database. Propensity score matching (PSM) was applied to reduce the baseline bias. Rectal NECs who underwent surgical resection plus chemotherapy with or without radiotherapy were extracted from SEER database. According to whether receiving radiotherapy, patients were divided into two cohorts: radiation treatment (RT) group and non-RT group. Overall survival (OS) was measured to assess the clinical benefits of RT. Kaplan-Meier survival analysis, univariable and multivariable regression analysis were applied.
resultsA total of 666 eligible patients were finally enrolled. The difference in OS remained significant both before and after PSM. Subgroup analyses revealed significantly better results for stage II, III and even IV patients who received radiotherapy whether before or after matching (all p < 0.05). The multivariable analysis showed that radiotherapy was associated with OS (HR 0.54; 95% CI 0.45 to 0.65; p < 0.001), together with distant metastasis. These results were consistent after matching (both p < 0.05).
conclusionsRadiotherapy was an independent favorable prognostic factor for rectal NECs. The addition of radiotherapy to surgery plus chemotherapy might improve the clinical outcome. In the future, well-designed prospective studies are needed to assess the potential role of radiation in managing surgically resectable rectal NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.